DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21

PRECISION BIOSCIENCES INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$6.19+0.42 (+7.28%)

Close on Oct 19, 2026

Market cap: $160.05M
P/E (TTM): –
Dividend yield: –

PRECISION BIOSCIENCES INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	34	69	49	25	116	24	22	11
Research & Development	54	60	53	46	115	98	82	45
General & Administrative	32	35	39	41	40	36	27	14
Operating Expenses	86	95	92	87	155	134	109	59
Operating Income	-52	-26	-44	-62	-39	-110	-87	-48
Interest Expense	1.42	1.78	2.23	1.11	0.13	–	0.18	–
Interest & Investment Income	4.24	6.76	7.69	3.47	0.21	0.82	4.27	1.88
Income from Equity Investments	-5.28	-1.08	-4.93	-1.58	0.18	–	–	–
Other Non-Operating Income	5.54	33	1.21	-11	8.77	0.82	-5.67	1.88
Asset Impairment Charges	0.04	0	–	11	–	–	–	–
Gain (Loss) on Investments	-2.67	0.26	1.15	-0.51	–	–	–	–
Gain (Loss) on Sale of Assets	-0.42	-0.44	-0.46	-0.03	-0.03	–	–	–
Pretax Income	-46	7.17	–	–	–	–	–	–
Income Tax Expense	0	0	–	–	–	0.02	–	–
Income from Continuing Operations	-47	7.17	-43	-73	–	–	–	–
Income from Discontinued Operations	0.89	0	-19	-39	–	–	–	–
Net Income incl. Noncontrolling Interests	-46	7.17	-61	-112	-31	-109	-93	-46
Net Income	-46	7.17	-61	-112	-31	-109	-93	-46
EPS (Basic)(per share)	-3.56	1.05	-15.96	-38.10	-15.60	-62.70	-66.30	-87.60
EPS (Diluted)(per share)	-3.56	1.04	-15.96	-38.10	-15.60	-62.70	-66.30	-87.60
Shares Outstanding (Basic, Weighted)(shares)	13	6.83	3.84	2.93	1.96	1.73	1.40	0.53
Shares Outstanding (Diluted, Weighted)(shares)	13	6.88	3.84	2.93	1.96	1.73	1.40	0.53
EBITDA	-51	-23	-37	-55	-30	-101	-82	-46

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -80.8%
Net margin: -117.0%
Return on equity, FY2025: -61.5%

Financial strength

Current ratio: 12.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1205.5%

Valuation

P/E ratio: –
Price to sales: 3.55
Price to book: 3.53
Dividend yield: –